Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

NCT05821192 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T-Cell Lymphoma, Not Otherwise Specified
Angioimmunoblastic T-cell Lymphoma

Interventions

DRUG: Rituximab
DRUG: Gemcitabine
DRUG: Dexamethasone
DRUG: Cisplatin
DRUG: PD-1 monoclonal antibody

Sponsor

Ou Bai, MD/PHD

Collaborators

[object Object]
[object Object]